Incidental genetic findings in randomized clinical trials

Recommendations from the Genomics and Randomized Trials Network (GARNET)

Ebony B. Bookman, Corina Din-Lovinescu, Bradford B. Worrall, Teri A. Manolio, Siiri N. Bennett, Cathy Laurie, Daniel B. Mirel, Kimberly F. Doheny, Garnet L. Anderson, Kate Wehr, Richard M Weinshilboum, Donna T. Chen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recommendations and guidance on how to handle the return of genetic results to patients have offered limited insight into how to approach incidental genetic findings in the context of clinical trials. This paper provides the Genomics and Randomized Trials Network (GARNET) recommendations on incidental genetic findings in the context of clinical trials, and discusses the ethical and practical issues considered in formulating our recommendations. There are arguments in support of as well as against returning incidental genetic findings in clinical trials. For instance, reporting incidental findings in clinical trials may improve the investigator-participant relationship and the satisfaction of participation, but it may also blur the line between clinical care and research. The issues of whether and how to return incidental genetic findings, including the costs of doing so, should be considered when developing clinical trial protocols. Once decided, plans related to sharing individual results from the aim(s) of the trial, as well as incidental findings, should be discussed explicitly in the consent form. Institutional Review Boards (IRBs) and other study-specific governing bodies should be part of the decision as to if, when, and how to return incidental findings, including when plans in this regard are being reconsidered.

Original languageEnglish (US)
Article number7
JournalGenome Medicine
Volume5
Issue number1
DOIs
StatePublished - Jan 30 2013

Fingerprint

Incidental Findings
Genomics
Randomized Controlled Trials
Clinical Trials
Clinical Protocols
Consent Forms
Research Ethics Committees
Ethics
Research Personnel
Costs and Cost Analysis
Research

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Bookman, E. B., Din-Lovinescu, C., Worrall, B. B., Manolio, T. A., Bennett, S. N., Laurie, C., ... Chen, D. T. (2013). Incidental genetic findings in randomized clinical trials: Recommendations from the Genomics and Randomized Trials Network (GARNET). Genome Medicine, 5(1), [7]. https://doi.org/10.1186/gm411

Incidental genetic findings in randomized clinical trials : Recommendations from the Genomics and Randomized Trials Network (GARNET). / Bookman, Ebony B.; Din-Lovinescu, Corina; Worrall, Bradford B.; Manolio, Teri A.; Bennett, Siiri N.; Laurie, Cathy; Mirel, Daniel B.; Doheny, Kimberly F.; Anderson, Garnet L.; Wehr, Kate; Weinshilboum, Richard M; Chen, Donna T.

In: Genome Medicine, Vol. 5, No. 1, 7, 30.01.2013.

Research output: Contribution to journalArticle

Bookman, EB, Din-Lovinescu, C, Worrall, BB, Manolio, TA, Bennett, SN, Laurie, C, Mirel, DB, Doheny, KF, Anderson, GL, Wehr, K, Weinshilboum, RM & Chen, DT 2013, 'Incidental genetic findings in randomized clinical trials: Recommendations from the Genomics and Randomized Trials Network (GARNET)', Genome Medicine, vol. 5, no. 1, 7. https://doi.org/10.1186/gm411
Bookman, Ebony B. ; Din-Lovinescu, Corina ; Worrall, Bradford B. ; Manolio, Teri A. ; Bennett, Siiri N. ; Laurie, Cathy ; Mirel, Daniel B. ; Doheny, Kimberly F. ; Anderson, Garnet L. ; Wehr, Kate ; Weinshilboum, Richard M ; Chen, Donna T. / Incidental genetic findings in randomized clinical trials : Recommendations from the Genomics and Randomized Trials Network (GARNET). In: Genome Medicine. 2013 ; Vol. 5, No. 1.
@article{d2f488b37abc4e3c97455ce2911ebddf,
title = "Incidental genetic findings in randomized clinical trials: Recommendations from the Genomics and Randomized Trials Network (GARNET)",
abstract = "Recommendations and guidance on how to handle the return of genetic results to patients have offered limited insight into how to approach incidental genetic findings in the context of clinical trials. This paper provides the Genomics and Randomized Trials Network (GARNET) recommendations on incidental genetic findings in the context of clinical trials, and discusses the ethical and practical issues considered in formulating our recommendations. There are arguments in support of as well as against returning incidental genetic findings in clinical trials. For instance, reporting incidental findings in clinical trials may improve the investigator-participant relationship and the satisfaction of participation, but it may also blur the line between clinical care and research. The issues of whether and how to return incidental genetic findings, including the costs of doing so, should be considered when developing clinical trial protocols. Once decided, plans related to sharing individual results from the aim(s) of the trial, as well as incidental findings, should be discussed explicitly in the consent form. Institutional Review Boards (IRBs) and other study-specific governing bodies should be part of the decision as to if, when, and how to return incidental findings, including when plans in this regard are being reconsidered.",
author = "Bookman, {Ebony B.} and Corina Din-Lovinescu and Worrall, {Bradford B.} and Manolio, {Teri A.} and Bennett, {Siiri N.} and Cathy Laurie and Mirel, {Daniel B.} and Doheny, {Kimberly F.} and Anderson, {Garnet L.} and Kate Wehr and Weinshilboum, {Richard M} and Chen, {Donna T.}",
year = "2013",
month = "1",
day = "30",
doi = "10.1186/gm411",
language = "English (US)",
volume = "5",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Incidental genetic findings in randomized clinical trials

T2 - Recommendations from the Genomics and Randomized Trials Network (GARNET)

AU - Bookman, Ebony B.

AU - Din-Lovinescu, Corina

AU - Worrall, Bradford B.

AU - Manolio, Teri A.

AU - Bennett, Siiri N.

AU - Laurie, Cathy

AU - Mirel, Daniel B.

AU - Doheny, Kimberly F.

AU - Anderson, Garnet L.

AU - Wehr, Kate

AU - Weinshilboum, Richard M

AU - Chen, Donna T.

PY - 2013/1/30

Y1 - 2013/1/30

N2 - Recommendations and guidance on how to handle the return of genetic results to patients have offered limited insight into how to approach incidental genetic findings in the context of clinical trials. This paper provides the Genomics and Randomized Trials Network (GARNET) recommendations on incidental genetic findings in the context of clinical trials, and discusses the ethical and practical issues considered in formulating our recommendations. There are arguments in support of as well as against returning incidental genetic findings in clinical trials. For instance, reporting incidental findings in clinical trials may improve the investigator-participant relationship and the satisfaction of participation, but it may also blur the line between clinical care and research. The issues of whether and how to return incidental genetic findings, including the costs of doing so, should be considered when developing clinical trial protocols. Once decided, plans related to sharing individual results from the aim(s) of the trial, as well as incidental findings, should be discussed explicitly in the consent form. Institutional Review Boards (IRBs) and other study-specific governing bodies should be part of the decision as to if, when, and how to return incidental findings, including when plans in this regard are being reconsidered.

AB - Recommendations and guidance on how to handle the return of genetic results to patients have offered limited insight into how to approach incidental genetic findings in the context of clinical trials. This paper provides the Genomics and Randomized Trials Network (GARNET) recommendations on incidental genetic findings in the context of clinical trials, and discusses the ethical and practical issues considered in formulating our recommendations. There are arguments in support of as well as against returning incidental genetic findings in clinical trials. For instance, reporting incidental findings in clinical trials may improve the investigator-participant relationship and the satisfaction of participation, but it may also blur the line between clinical care and research. The issues of whether and how to return incidental genetic findings, including the costs of doing so, should be considered when developing clinical trial protocols. Once decided, plans related to sharing individual results from the aim(s) of the trial, as well as incidental findings, should be discussed explicitly in the consent form. Institutional Review Boards (IRBs) and other study-specific governing bodies should be part of the decision as to if, when, and how to return incidental findings, including when plans in this regard are being reconsidered.

UR - http://www.scopus.com/inward/record.url?scp=84873042619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873042619&partnerID=8YFLogxK

U2 - 10.1186/gm411

DO - 10.1186/gm411

M3 - Article

VL - 5

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 1

M1 - 7

ER -